Research Article

Infections due to Carbapenem Resistant Enterobacteriaceae among Saudi Arabian Hospitalized Patients: A Matched Case-Control Study

Table 4

Univariate analysis of factors associated with 30-day mortality.

VariableNonsurvivors ()Survivors ()OR (95% CI) value

Age66.9 ± 4.1 (37, 89)52.2 ± 2.3 (15, 94)0.007
Gender 3.98 (0.94–19.40)0.064
 Male13 (26.0)37 (74.0)
 Female3 (8.1)34 (91.9)
Admission site9.04 (2.10–44.77)<0.001
 ICU13 (36.1)23 (63.9)
 Medical 1 (2.9)34 (97.1)
 Surgical 2 (12.5)14 (87.5)
Pulmonary disease8.86 (2.28–35.86)<0.001
 No7 (10.1)62 (89.9)
 Yes9 (50.0)9 (50.0)
Renal disease3.78 (1.08–13.49)0.034
 No7 (11.7)53 (88.3)
 Yes9 (33.3)18 (66.7)
Immunotherapy 5.45 (1.46–20.78)0.007
 No8 (11.8)60 (88.2)
 Yes8 (42.1)11 (57.9)
CVP line49.14 (3.64–27367830.40)<0.001
 No0 (.0)43 (100.0)
 Yes16 (36.4)28 (63.6)
Foley catheter7.28 (1.35–51.82)0.015
 No2 (7.1)26 (92.9)
 Yes14 (23.7)45 (76.3)
Stayed in ICU34.82 (2.59–19367353.0)<0.001
 No0 (.0)37 (100.0)
 Yes16 (32.0)34 (68.0)
Mechanical ventilation29.37 (3.65–632.02)<0.001
 No1 (2.1)47 (97.9)
 Yes15 (38.5)24 (61.5)
Carbapenem3.79 (1.08–13.49)0.034
 No7 (11.7)53 (88.3)
 Yes9 (33.3)18 (66.7)
Tigecycline10.30 (1.77–65.67)0.004
 No11 (13.9)68 (86.1)
 Yes5 (62.5)3 (37.5)